期刊
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
卷 26, 期 3, 页码 649-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.hoc.2012.02.012
关键词
Poly(ADP-ribose) polymerase; Inhibitor; Synthetic lethality; BRCA
资金
- Intramural NIH HHS [Z99 CA999999] Funding Source: Medline
- NCI NIH HHS [Y99 CA999999] Funding Source: Medline
Recently, the development of poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors as a synthetic lethality approach has brought a major breakthrough in the treatment of breast cancer susceptibility gene (BRCA)-mutant cancers. Because sporadic cancers have also been found to commonly have other defects in DNA repair, PARP inhibitors are under active clinical investigation in combination with DNA-damaging therapeutics in a wide range of sporadic cancers. In this review, the authors discuss DNA repair mechanisms and PARP as a therapeutic target and summarize an update on clinical trials of available PARP inhibitors and predictive biomarkers for their efficacy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据